Riskpilot← Back to searchSign inGet full accessCG Biology AB
ABActiveOrg 5591395164Kängsta 32Business and other management consultancy activities · NACE 7020Est. 20172 employees
Revenue 2025
SEK 1M
-65% vs 2024
EBITDA margin
39.7%
-77% vs 2024
Equity ratio
57.2%
Financial strength
Net profit 2025
SEK 430K
-50% vs 2024
| Revenue | SEK 1M | -65% |
| EBITDA | SEK 406K | -77% |
| Net profit | SEK 430K | -50% |
| Total assets | SEK 9,2M | -7% |
| Equity | SEK 5,3M | +9% |
| Employees | 2 | — |
Legal name
CG Biology AB
Org number
5591395164
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
14 december 2017
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska driva konsulttjänster och produktförsäljning inom cellulära och molekylära biologiska marknader, jordbruk, hyresfastigheter, och värdepapper samt förenlig verksamhet.
Address
Kängsta 32
Email
steve_glavas@yahoo.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 681 | 2 509 | 1 164 | 2 954 | 1 022 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 468 | 1 322 | 478 | 1 795 | 406 |
| Depreciation & amort. | −177 | −186 | −263 | −355 | −315 |
| EBIT | 291 | 1 136 | 215 | 1 440 | 91 |
| Net financials | — | −2 | −74 | −193 | −149 |
| Profit before tax | 291 | 850 | 292 | 1 090 | 546 |
| Tax | −377 | −176 | −65 | −232 | −116 |
| Net profit | −86 | 674 | 227 | 858 | 430 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 318 | 5 293 | 9 040 | 9 956 | 9 240 |
| Equity | 3 093 | 3 767 | 3 994 | 4 852 | 5 281 |
| Long-term debt | 0 | 0 | 4 080 | 4 080 | 3 600 |
| Short-term debt | 912 | 929 | 519 | 421 | 358 |
| Total debt | 912 | 929 | 4 599 | 4 501 | 3 958 |
EBITDA margin
39.7%
This company
15.8%
Market median
+151% vs market
20212025
Equity ratio
57.2%
This company
38.2%
Market median
+50% vs market
20212025
Return on equity
8.1%
This company
18.4%
Market median
-56% vs market
20212025
Net profit margin
42.1%
This company
8.1%
Market median
+420% vs market
20212025
Asset turnover
0.11×
This company
1.12×
Market median
-90% vs market
20212025
Debt / equity
0.75×
This company
0.62×
Market median
+21% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CG Biology AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Charles Steven Glavas | Board of Directors | 0 companies |
| Carin Elin Carlsson | Deputy Board Member | 0 companies |